Home » Newsletters » BioWorld Science

BioWorld Science

April 16, 2020

View Archived Issues

The next pandemic: speeding development and stretching supplies

Gut repair with an iron will

Eight newly identified loci are involved in the susceptibility to cutaneous SCC, large GWAS shows

Rac1 overexpression is involved in breast cancer chemoresistance by influencing DNA damage repair

FDA authorizes phase II study of MultiStem cell therapy in trauma patients

Chinese regulatory approval granted to initiate phase II/III study of HBM-9161 in ITP

TScan and Novartis collaborate to develop novel TCR-engineered T-cell therapies

Novel hBCR/ABL1-induced zebrafish model of CML

EM2D9 antibody shows potent antitumor activity in preclinical models of endometrial cancer

New Toll-like receptor 7 agonists discovered at Bristol-Myers Squibb

Shenzhen Edk Pharmaceutical Technology patents androgen receptor antagonists

Betta Pharmaceuticals discloses new FGFR-4 inhibitors

Shanghai Ennova Biopharmaceutical describes new SSAO inhibitors

OncoImmune initiates phase III study with CD24Fc for COVID-19

New MAP3K5 inhibitors identified at XuanZhu Pharma

New ANKRD26-RET fusion gene found in papillary thyroid carcinoma

Galapagos and Ryvu establish research collaboration in inflammation

Roivant initiates pivotal trial of gimsilumab for prevention and treatment of COVID-19-related ARDS

FDA approves Jelmyto for low-grade upper tract urothelial cancer

Vir reports interim data from ongoing phase II study of VIR-2218 for chronic HBV infection

SPL-7013 demonstrates significant activity against SARS-CoV-2 in lab studies

Gilead Sciences begins phase III trial of remdesivir for the treatment of COVID-19 in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...